SAGE Therapeutics Inc logo

SAGE - SAGE Therapeutics Inc Share Price

$74.37 0.9  1.3%

Last Trade - 21/04/21

Large Cap
Market Cap £3.12bn
Enterprise Value £1.61bn
Revenue £799.9m
Position in Universe 1524th / 6852
Unlock SAGE Revenue
Relative Strength (%)
1m -11.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -24.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 90.3 6.87 1,114 16.9 135.6
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, SAGETherapeutics Inc revenues increased from $6.9M to $1.11B.Net income totaled $606.1M vs. loss of $680.2M. Revenuesreflect Collaboration revenue increase from $2.9M to $1.11B, Product increase of 69% to $6.7M. Net Income reflectsGeneral & admi decrease of 43% to $145.1M (expense), R & Dexp decrease of 18% to $250.3M (expense), Stock-basedCompensation in SGA decrease of 43% to $51.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for SAGE
Graphical History


SAGE Revenue Unlock SAGE Revenue

Net Income

SAGE Net Income Unlock SAGE Revenue

Normalised EPS

SAGE Normalised EPS Unlock SAGE Revenue

PE Ratio Range

SAGE PE Ratio Range Unlock SAGE Revenue

Dividend Yield Range

SAGE Dividend Yield Range Unlock SAGE Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
SAGE EPS Forecasts Unlock SAGE Revenue
Profile Summary

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. The Company's next-generation product candidates, SAGE-217 and SAGE-689, also target the GABAA receptor system. The Company is focused on developing drugs based on selective allosteric modulation of CNS synaptic and extrasynaptic receptors. The Company's chemistry platform is focused on the chemical scaffolds of endogenous or chemically modified synthetic neuroactive steroid compounds that are allosteric modulators of GABAA or N-Methyl-D-aspartic acid or N-Methyl-D-aspartate (NMDA) receptors.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated April 16, 2010
Public Since July 18, 2014
No. of Shareholders: 6
No. of Employees: 298
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 58,381,933
Free Float (0.0%)
Eligible for
SAGE Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for SAGE
Upcoming Events for SAGE
Tuesday 4th May, 2021
Q1 2021 SAGE Therapeutics Inc Earnings Call
Tuesday 4th May, 2021
Q1 2021 SAGE Therapeutics Inc Earnings Release
Wednesday 9th June, 2021 Estimate
SAGE Therapeutics Inc Annual Shareholders Meeting
Monday 9th August, 2021 Estimate
Q2 2021 SAGE Therapeutics Inc Earnings Release
Frequently Asked Questions for SAGE Therapeutics Inc
What is the SAGE Therapeutics Inc share price?

As of 21/04/21, shares in SAGE Therapeutics Inc are trading at $74.37, giving the company a market capitalisation of £3.12bn. This share price information is delayed by 15 minutes.

How has the SAGE Therapeutics Inc share price performed this year?

Shares in SAGE Therapeutics Inc are currently trading at $74.37 and the price has moved by 0.117k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the SAGE Therapeutics Inc price has moved by 47.17% over the past year.

What are the analyst and broker recommendations for SAGE Therapeutics Inc?

Of the analysts with advisory recommendations for SAGE Therapeutics Inc, there are there are currently 10 "buy" , 8 "hold" and 0 "sell" recommendations. The overall consensus recommendation for SAGE Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will SAGE Therapeutics Inc next release its financial results?

SAGE Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the SAGE Therapeutics Inc dividend yield?

SAGE Therapeutics Inc does not currently pay a dividend.

Does SAGE Therapeutics Inc pay a dividend?

SAGE Therapeutics Inc does not currently pay a dividend.

When does SAGE Therapeutics Inc next pay dividends?

SAGE Therapeutics Inc does not currently pay a dividend.

How do I buy SAGE Therapeutics Inc shares?

To buy shares in SAGE Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of SAGE Therapeutics Inc?

Shares in SAGE Therapeutics Inc are currently trading at $74.37, giving the company a market capitalisation of £3.12bn.

Where are SAGE Therapeutics Inc shares listed? Where are SAGE Therapeutics Inc shares listed?

Here are the trading details for SAGE Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: SAGE
What kind of share is SAGE Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, SAGE Therapeutics Inc is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a SAGE Therapeutics Inc share price forecast 2021?

Shares in SAGE Therapeutics Inc are currently priced at $74.37. At that level they are trading at 36.88% discount to the analyst consensus target price of 0.00.

Analysts covering SAGE Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -7.787 for the next financial year.

How can I tell whether the SAGE Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like SAGE Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been -14.46%. At the current price of $74.37, shares in SAGE Therapeutics Inc are trading at 7.05% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the SAGE Therapeutics Inc PE Ratio?

The SAGE Therapeutics Inc PE ratio based on its reported earnings over the past 12 months is 6.22. The shares are currently trading at $74.37.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of SAGE Therapeutics Inc?

SAGE Therapeutics Inc's management team is headed by:

Kevin Starr - CHM
Albert Robichaud - CSO
Jeffrey Jonas - OTH
Stephen Kanes - OTH
Kimi Iguchi - CFO
James Frates - IND
Michael Cola - IND
Geno Germano - IND
Anne Cook - SVP
Michael Cloonan - COO
Elizabeth Barrett - IND
George Golumbeski - IND
Barry Greene - CEO
Who are the major shareholders of SAGE Therapeutics Inc?

Here are the top five shareholders of SAGE Therapeutics Inc based on the size of their shareholding:

Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 13.26% (7.74m shares)
Biogen Inc Corporation
Percentage owned: 10.69% (6.24m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.88% (4.60m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 7.34% (4.28m shares)
Fidelity Growth Company Fund Mutual Fund
Percentage owned: 4.3% (2.51m shares)
Similar to SAGE
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.